Other Events. On August 5, 2026, the Board of Directors of the Company approved a share repurchase program, which authorizes the Company to repurchase up to $100 million of the Company's outstanding shares of common stock (the "Repurchase Program"). The Repurchase Program replaces the Company's prior $100 million repurchase program approved by the Board of Directors of the Company on February 24, 2026. The Repurchase Program does not obligate the Company to repurchase any particular amount of…

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Director — Jeffrey Rhodes: Mr. Rhodes resigned from the Board and all of its committees.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

COO — Lisa Miller: The filing discloses the internal promotion of Lisa Miller from EVP to Chief Operating Officer, which is a succession event rather than a departure.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Other Items. On February 24, 2026, the Board of Directors of the Company approved a share repurchase program, which authorizes the Company to repurchase up to $100 million of the Company’s outstanding shares of common stock (the “Repurchase Program”). The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock. Stock repurchases under this program may be made at such times, prices, amounts and on such terms as the Company may determine from time to…

Executive Chairman — Kenneth Burdick: The Executive Chairman is transitioning to a non-executive role rather than leaving the company, which is a change in duties rather than a departure.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Director — William Miller: A director resigned immediately without disagreement and was promptly replaced by a new appointment, indicating an orderly board change rather than a senior executive loss.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Chief Digital Officer — Pablo Pantaleoni: The Chief Digital Officer is departing with a separation agreement, representing a genuine executive departure, though the role is not typically considered a C-suite officer like CEO or CFO.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

CEO — Kenneth Burdick: The CEO is retiring with a named internal successor (CFO promoted to CEO) and a new external CFO hired, representing an orderly succession rather than a sudden loss of leadership.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Termination of a Material Definitive Agreement. The information included in

Entry into a Material Definitive Agreement. On December 19, 2024 (the “Closing Date”), LifeStance Health Holdings, Inc. (the “Borrower”), a subsidiary of LifeStance Health Group, Inc. (“LifeStance Health Group” or the “Company”) entered into a credit agreement (the “2024 Credit Agreement”) among the Borrower, Lynnwood Intermediate Holdings, Inc., a wholly-owned subsidiary of the Company (“Holdings”), the other guarantors party thereto, Capital One, National Association, as administrative agen…

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. LifeStance Health Group, Inc. Date: December 19, 2024 By: /s/ David Bourdon David Bourdon Chief Financial Officer and Treasurer (principal financial and accounting officer)

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

President and Chief Operating Officer — Danish Qureshi: The President and COO's employment was terminated, representing the loss of a senior executive without an immediate named successor.

COO — Danish Qureshi: The President and Chief Operating Officer is resigning, representing the loss of a key senior executive.

of this Current Report on Form 8-K, including the exhibit, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into LifeStance Health Group's filings with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Director — Teresa DeLuca: The filing discloses the appointment of a new director, which is a routine board composition change and not a departure of a senior executive.